Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SeVRSV
- Development stage
- Phase 1
- Lead developer
- St. Jude Children's Research Hospital
- Modality
- Viral Vectors → Gene Addition/Replacement → Gene Therapies, Vaccines & Immunotherapeutics
- Administration
- Intranasal
01
Overview
SeVRSV is a live-attenuated, recombinant viral vector vaccine candidate designed to provide bivalent protection against respiratory syncytial virus (RSV) and human parainfluenza virus type 1 (hPIV1). Developed by St. Jude Children's Research Hospital, the vaccine utilizes the Sendai virus (SeV)—a murine parainfluenza virus—as a vector to express the RSV fusion (F) protein. Because SeV is antigenically related to hPIV1, the vector backbone itself induces cross-reactive immunity against hPIV1, while the expressed F protein induces neutralizing antibodies and T-cell responses against RSV. The vaccine is typically administered intranasally to stimulate mucosal immunity in the upper respiratory tract, mimicking natural infection to prevent lower respiratory tract disease in infants and children.
- Other names
- rSeV-RSV-FSendai virus-RSV vaccinerecombinant Sendai virus expressing RSV F protein
02
Targets
RSV F (Respiratory syncytial virus fusion protein)
Beyond the preview
Go deeper on SeVRSV.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SeVRSV.